Analysts predict that Spark Therapeutics Inc (NASDAQ:ONCE) will announce sales of $53.75 million for the current quarter, according to Zacks. Eight analysts have made estimates for Spark Therapeutics’ earnings. The lowest sales estimate is $3.00 million and the highest is $119.00 million. Spark Therapeutics posted sales of $1.27 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 4,132.3%. The firm is expected to issue its next quarterly earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Spark Therapeutics will report full-year sales of $53.75 million for the current financial year, with estimates ranging from $80.00 million to $239.52 million. For the next financial year, analysts anticipate that the company will post sales of $152.05 million per share, with estimates ranging from $76.99 million to $229.40 million. Zacks’ sales averages are an average based on a survey of research firms that cover Spark Therapeutics.
Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.73). Spark Therapeutics had a negative return on equity of 59.38% and a negative net margin of 2,100.80%. The company had revenue of $7.41 million for the quarter, compared to analyst estimates of $9.53 million.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Xact Kapitalforvaltning AB bought a new position in Spark Therapeutics during the fourth quarter valued at about $208,000. HighPoint Advisor Group LLC bought a new position in Spark Therapeutics during the fourth quarter valued at about $419,000. Sabby Management LLC bought a new position in Spark Therapeutics during the fourth quarter valued at about $5,699,000. MetLife Investment Advisors LLC bought a new position in Spark Therapeutics during the fourth quarter valued at about $647,000. Finally, Element Capital Management LLC bought a new position in Spark Therapeutics during the fourth quarter valued at about $8,021,000.
Spark Therapeutics (ONCE) traded up $1.95 during midday trading on Friday, reaching $65.58. The company’s stock had a trading volume of 393,036 shares, compared to its average volume of 763,294. Spark Therapeutics has a one year low of $41.06 and a one year high of $91.75. The company has a market capitalization of $2,380.00, a price-to-earnings ratio of -8.47 and a beta of 2.81.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.themarketsdaily.com/2018/03/14/brokerages-expect-spark-therapeutics-inc-once-will-announce-quarterly-sales-of-53-75-million.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.